Neuraltus Pharmaceuticals, Inc.: Series B $9.6M

Posted in I - Series B, Q - 4Q11, R - WEST, X - ALS, X - Alzheimer's, X - Lysosomal Storage, X - Multiple Sclerosis, X - Neuro Degenerative, X - Parkinson's, XX - CA

Neuraltus Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on small molecule drugs for the neurodegenerative diseases such as ALS multiple sclerosis, Parkinson’s, Alzheimer’s, Fabry’s and Gaucher’s diseases, closed a $9.6M Series B financing. Participants include Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

Oct

2010

iPierian, Inc.: Series B $6M

Posted in I - Series B, Q - 3Q10, R - WEST, X - ALS, X - Parkinson's, X - Stem Cell, XX - CA

iPierian (San Francisco, CA) a development-stage induced pluripotent stem cell (iPSC) drug discovery company focused upon neurodegenerative disease including ALS and Parkinson’s, closed a $6M Series B financing, bring the round total to $28M. Participants include SR One, Biogen Idec, Google Ventures, Mitsubishi UFJ Capital, ATEL Ventures, MPM Capital, Highland Capital Partners and Kleiner Perkins [...]

Aug

2010

iPierian, Inc.: Series B $22M

Posted in I - Series B, Q - 3Q10, R - WEST, X - ALS, X - Parkinson's, X - Stem Cell, XX - CA

iPerian (San Francisco, CA) a development-stage induced pluripotent stem cell drug discovery company focused upon neurodegenerative disease including ALS and Parkinson’s, closed a $22M Series B financing. Participants include Google Ventures, Mitsubishi UFJ Capital, ATEL Ventures, MPM Capital, Highland Capital Partners and Kleiner Perkins Caufield & Byers.

Mar

2009

Neuraltus Pharmaceuticals, Inc.: Series A $17M

Posted in I - Series A, Q - 1Q09, R - WEST, X - ALS, X - Dyskinesia, X - Neurology, XX - CA

Neuraltus Pharmaceuticals (Menlo Park, CA) a preclinical-stage developer of small-molecule drugs focused on Amyotropic Lateral Sclerosis and dyskinesia, closed a $17M Series A financing. Participants include Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

Dec

2008

Knopp Neurosciences, Inc.: Series B $27M

Posted in I - Series B, Q - 4Q08, R - NORTH EAST, X - ALS, X - CNS

Knopp Neurosciences (Pittsburgh, PA) early-stage drug discovery and development company focused on amyotrophic lateral sclerosis and other neurological disorders, closed a $27M Series B financing. Participants include Saturn Partners, Kramer Capital Partners and LaunchCyte.

Dec

2008

Link Medicine Corp.: Series C $40M

Posted in I - Series C, R - NORTH EAST, X - ALS, X - Alzheimer's, X - Neurology

Link Medicine (Cambridge, MA) development-stage company focused on the treatment of several neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, and Amyotrophic Lateral Sclerosis, closed a $40M Series C financing. Participants include Clarus Ventures and SV Life Sciences.

Feb

2008

Knopp Neurosciences, Inc.: Series B $10M

Posted in I - Series B, Q - 1Q08, R - NORTH EAST, X - ALS, X - Neurology

Knopp Neurosciences (Pittsburgh, PA) a drug discovery and development company focused on neurological disorders with a lead compound for amyotrophic lateral sclerosis closed a $10M Series B financing. Participants include Saturn Partners, Kramer Capital Partners and LaunchCyte.

to top of page...